Overview

Window Trial 5-aza in HNSCC, T-tare

Status:
Recruiting

Trial end date:
2021-11-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to assess the activity of 5-azacitidine in patients with Human Papilloma Virus (HPV)-positive and HPV- negative head and neck squamous cell carcinoma (HNSCC). The response activity will be determined by analyzing your tumor tissue prior to and after treatment with 5-azacitidine. Preliminary studies in mice bearing human head and neck cancers or head and neck cancer cells cultured in laboratories suggest that treatment with 5-azacitidine increases changes in cancer cells that lead to their death. This study is designed to determine if similar changes occur in cancer cells of patients with head and neck cancer. The study also aims to determine the amount of a specific type of protein, p53 before and after treatment. Research has shown that the p53 protein is associated with anti-tumor activity. Finally, this study is measuring the amount of a specific type of protein called interferon in your tumor tissue. Interferons are proteins made and released by the body in response to pathogens (disease causing agents) such as viruses, bacteria, or tumor cells. Interferons allow for communication between cells to trigger the protective defenses of the immune system that remove pathogens (disease causing agents) or tumors.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Yale University

Criteria

Inclusion Criteria:

1. Histologically confirmed p16 or HPV PCR positive HNSCC with surgically resectable
disease

2. Age ≥18 years of age.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2

4. ANC greater than or equal to 1500, Hb greater than or equal to 8, platelet count
greater than or equal to 100,000

Exclusion Criteria:

1. AST or ALT greater than 2.5 x ULN

2. Known brain metastases

3. Women must not be pregnant or breastfeeding

4. Known allergy to 5-azacitadine

5. Patients receiving any other investigational agents within 4 weeks of starting the
study